New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
07:17 EDTCYCCCyclacel receives U.S., EU patents for sapacitabine used with HDAC inhibitors
Cyclacel Pharmaceuticals announced the issuance of U.S. Patent No. U.S. 8,349,792 and European Patent No 2,101,790. Both patents include claims to combination treatment of sapacitabine, the Company's lead product candidate, with histone deacetylase, or HDAC, inhibitors. The patents provide exclusivity until June 2029 and December 2027 respectively.
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
06:18 EDTCYCCCyclacel downgraded to Market Perform from Outperform at JMP Securities
Subscribe for More Information
December 16, 2014
09:16 EDTCYCCOn The Fly: Pre-market Movers
Subscribe for More Information
07:41 EDTCYCCCyclacel Pharmaceuticals to host conference call
Subscribe for More Information
07:11 EDTCYCCCyclacel announces sapacitabine Phase 3 trial continues to final analysis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use